Cardioselective antiischemic ATP-sensitive potassium channel (KATP) openers. 5. Identification of 4-(N-aryl)-substituted benzopyran derivatives with high selectivity. 1997

G C Rovnyak, and S Z Ahmed, and C Z Ding, and S Dzwonczyk, and F N Ferrara, and W G Humphreys, and G J Grover, and D Santafianos, and K S Atwal, and A J Baird, and L G McLaughlin, and D E Normandin, and P G Sleph, and S C Traeger
Bristol-Myers Squibb Pharmoceutical Research Institute, Princeton, New Jersey 08543-4000, USA.

This paper describes our studies aimed at the discovery of structurally distinct analogs of the cardioprotective KATP opener BMS-180448 (2) with improved selectivity for the ischemic myocardium. The starting compound 6, derived from the indole analog 4. showed good cardioprotective potency and excellent selectivity compared to 2 and the first-generation KATP opener cromakalim (1). The structure-activity studies indicate that increasing the size of the alkyl ester leads to diminished potency as does its replacement with a variety of other groups (nitrile, methyl sulfone). Replacement of the ethyl ester of 6 with an imidazole gave the best compound 3 (BMS-191095) of this series which maintains the potency and selectivity of its predecessor 6. The results described in this publication further support that there is no correlation between vasorelaxant and cardioprotective potencies of KATP openers. Compound 3 is over 20- and 4000-fold more selective for the ischemic myocardium than 2 and cromakalim (1), respectively. The selectivity for the ischemic myocardium is achieved by reduction of vasorelaxant potency rather than enhancement in antiischemic potency. As for cromakalim (1) and 2, the cardioprotective effects of compound 3 are inhibited by cotreatment with the KATP blocker glyburide, indicating that the KATP opening is involved in its mechanism of cardioprotection. With its good oral bioavailability (47%) and plasma elimination half-life (3 h) in rats, compound 3 offers an excellent candidate to investigate the role of residual vasorelaxant potency of 2 toward its cardioprotective activity in vivo.

UI MeSH Term Description Entries
D005905 Glyburide An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide Glibenclamide,Daonil,Diabeta,Euglucon 5,Euglucon N,Glybenclamide,HB-419,HB-420,Maninil,Micronase,Neogluconin,HB 419,HB 420,HB419,HB420
D006321 Heart The hollow, muscular organ that maintains the circulation of the blood. Hearts
D000255 Adenosine Triphosphate An adenine nucleotide containing three phosphate groups esterified to the sugar moiety. In addition to its crucial roles in metabolism adenosine triphosphate is a neurotransmitter. ATP,Adenosine Triphosphate, Calcium Salt,Adenosine Triphosphate, Chromium Salt,Adenosine Triphosphate, Magnesium Salt,Adenosine Triphosphate, Manganese Salt,Adenylpyrophosphate,CaATP,CrATP,Manganese Adenosine Triphosphate,MgATP,MnATP,ATP-MgCl2,Adenosine Triphosphate, Chromium Ammonium Salt,Adenosine Triphosphate, Magnesium Chloride,Atriphos,Chromium Adenosine Triphosphate,Cr(H2O)4 ATP,Magnesium Adenosine Triphosphate,Striadyne,ATP MgCl2
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001578 Benzopyrans Compounds with a core of fused benzo-pyran rings. Benzopyran,Chromene,Chromenes
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015221 Potassium Channels Cell membrane glycoproteins that are selectively permeable to potassium ions. At least eight major groups of K channels exist and they are made up of dozens of different subunits. Ion Channels, Potassium,Ion Channel, Potassium,Potassium Channel,Potassium Ion Channels,Channel, Potassium,Channel, Potassium Ion,Channels, Potassium,Channels, Potassium Ion,Potassium Ion Channel
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus

Related Publications

G C Rovnyak, and S Z Ahmed, and C Z Ding, and S Dzwonczyk, and F N Ferrara, and W G Humphreys, and G J Grover, and D Santafianos, and K S Atwal, and A J Baird, and L G McLaughlin, and D E Normandin, and P G Sleph, and S C Traeger
January 1996, Journal of medicinal chemistry,
G C Rovnyak, and S Z Ahmed, and C Z Ding, and S Dzwonczyk, and F N Ferrara, and W G Humphreys, and G J Grover, and D Santafianos, and K S Atwal, and A J Baird, and L G McLaughlin, and D E Normandin, and P G Sleph, and S C Traeger
May 1995, Journal of medicinal chemistry,
G C Rovnyak, and S Z Ahmed, and C Z Ding, and S Dzwonczyk, and F N Ferrara, and W G Humphreys, and G J Grover, and D Santafianos, and K S Atwal, and A J Baird, and L G McLaughlin, and D E Normandin, and P G Sleph, and S C Traeger
November 1993, Journal of medicinal chemistry,
G C Rovnyak, and S Z Ahmed, and C Z Ding, and S Dzwonczyk, and F N Ferrara, and W G Humphreys, and G J Grover, and D Santafianos, and K S Atwal, and A J Baird, and L G McLaughlin, and D E Normandin, and P G Sleph, and S C Traeger
May 2003, European journal of medicinal chemistry,
G C Rovnyak, and S Z Ahmed, and C Z Ding, and S Dzwonczyk, and F N Ferrara, and W G Humphreys, and G J Grover, and D Santafianos, and K S Atwal, and A J Baird, and L G McLaughlin, and D E Normandin, and P G Sleph, and S C Traeger
October 2013, Mini reviews in medicinal chemistry,
G C Rovnyak, and S Z Ahmed, and C Z Ding, and S Dzwonczyk, and F N Ferrara, and W G Humphreys, and G J Grover, and D Santafianos, and K S Atwal, and A J Baird, and L G McLaughlin, and D E Normandin, and P G Sleph, and S C Traeger
December 2006, Journal of medicinal chemistry,
G C Rovnyak, and S Z Ahmed, and C Z Ding, and S Dzwonczyk, and F N Ferrara, and W G Humphreys, and G J Grover, and D Santafianos, and K S Atwal, and A J Baird, and L G McLaughlin, and D E Normandin, and P G Sleph, and S C Traeger
January 2007, Current medicinal chemistry,
G C Rovnyak, and S Z Ahmed, and C Z Ding, and S Dzwonczyk, and F N Ferrara, and W G Humphreys, and G J Grover, and D Santafianos, and K S Atwal, and A J Baird, and L G McLaughlin, and D E Normandin, and P G Sleph, and S C Traeger
April 1997, Canadian journal of physiology and pharmacology,
G C Rovnyak, and S Z Ahmed, and C Z Ding, and S Dzwonczyk, and F N Ferrara, and W G Humphreys, and G J Grover, and D Santafianos, and K S Atwal, and A J Baird, and L G McLaughlin, and D E Normandin, and P G Sleph, and S C Traeger
June 1994, Cardiovascular research,
G C Rovnyak, and S Z Ahmed, and C Z Ding, and S Dzwonczyk, and F N Ferrara, and W G Humphreys, and G J Grover, and D Santafianos, and K S Atwal, and A J Baird, and L G McLaughlin, and D E Normandin, and P G Sleph, and S C Traeger
June 2000, Bioorganic & medicinal chemistry,
Copied contents to your clipboard!